Cas:305371-97-5 2-ethenyl-1,4-difluorobenzene manufacturer & supplier

We serve Chemical Name:2-ethenyl-1,4-difluorobenzene CAS:305371-97-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-ethenyl-1,4-difluorobenzene

Chemical Name:2-ethenyl-1,4-difluorobenzene
CAS.NO:305371-97-5
Synonyms:2,5-Difluorostyrene;PC6275;1,4-Difluoro-2-vinyl-benzene
Molecular Formula:C8H6F2
Molecular Weight:140.13000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:143.998ºC at 760 mmHg
Density:1.132g/cm3
Index of Refraction:1.512
PSA:
Exact Mass:140.04400
LogP:2.60780

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,5-Difluorostyrene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-Difluoro-2-vinyl-benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-Difluoro-2-vinyl-benzene Use and application,PC6275 technical grade,usp/ep/jp grade.


Related News: The FDA said its decision allows for the J&J doses to be used in the United States or exported. T 2-ethenyl-1,4-difluorobenzene manufacturer The FDA said its decision allows for the J&J doses to be used in the United States or exported. T 2-ethenyl-1,4-difluorobenzene supplier At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. 2-ethenyl-1,4-difluorobenzene vendor Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. 2-ethenyl-1,4-difluorobenzene factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.